Skip to main content

Table 2 Non-hematologic toxicity

From: A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer

  Grade of toxicity (NCI-CTVAE grade v2.0)
1 2 3 4
n(%) n(%) n(%) n(%)
Arthralgia 23(31) 2(3) 1(1) 0(0)
Myalgia 29(39) 4(5) 0(0) 0(0)
Nausea 36(49) 12(16) 4(5) 0(0)
Vomiting 9(12) 7(9) 4(5) 0(0)
Mucositis/Stomatitis 21(28) 13(18) 0(0) 0(0)
Neurohearing 3(4) 1(1) 0(0) 0(0)
Neuromotor 2(3) 1(1) 0(0) 0(0)
Neurosensory 34(46) 4(5) 1(1) 0(0)
Edema 13(18) 4(5) 0(0) 0(0)
Fatigue 24(32) 18(24) 0(0) 0(0)
Change of taste 13(18) 4(5) 0(0) 0(0)
Anorexia/weight loss 2(3) 1(1) 0(0) 0(0)
Diarhoe 6(8) 0(0) 0(0) 0(0)
Nail changes 6(8) 5(7) 0(0) 0(0)
Rash 2(3) 1(1) 0(0) 0(0)
Epiphora 1(1) 2(3) 0(0) 0(0)
  1. NCI-CTCAE: National Cancer Institute Common Toxicity Criteria for Adverse Events.